Clinical genomic sequencing of pediatric and adult osteosarcoma reveals distinct molecular subsets with potentially targetable alterations.

CONCLUSIONS: We found potentially clinically actionable alterations in approximately 21% of OS patients. Additionally, at least 40% of patients have tumors harboring PDGFRA or VEGFA amplification, representing candidate subsets for clinical evaluation of additional therapeutic options. We propose a new genomically-based algorithm for directing OS patients to clinical trial options.
PMID: 31175097 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - June 6, 2019 Category: Cancer & Oncology Authors: Suehara Y, Alex D, Bowman AS, Middha S, Zehir A, Chakravarty D, Wang L, Jour G, Nafa K, Hayashi T, Jungbluth AA, Frosina D, Slotkin EK, Shukla NN, Meyers PA, Healey JH, Hameed M, Ladanyi M Tags: Clin Cancer Res Source Type: research